Synergistic effect of amphotericin B and tyrosol on biofilm formed by Candida krusei and Candida tropicalis from intrauterine device users

Santhanam Shanmughapriya, Haridevvenkatesan Sornakumari, Arumugam Lency, Senthil Kavitha, Kalimuthusamy Natarajaseenivasan

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The presence of intrauterine contraceptive devices (IUDs) provides a solid surface for attachment of microorganisms and an ideal niche for the biofilm to form and flourish. Vaginal candidiasis is often associated with the use of IUDs. Treatment of vaginal candidiasis that develops in connection with IUD use requires their immediate removal. Here, we present in vitro evidence to support the use of combination therapy to inhibit Candida biofilm. Twenty-three clinical Candida isolates (10 C. krusei and 13 C. tropicalis) recovered from endocervical swabs obtained from IUD and non-IUD users were assessed for biofilm-formation ability. The rate of isolation of Candida did not differ significantly among IUD and non-IUD users (P = 0.183), but the biofilm-formation ability of isolates differed significantly (P = 0.02). An in vitro biofilm model with the obtained isolates was subjected to treatment with amphotericin B, tyrosol, and a combination of amphotericin B and tyrosol. Inhibition of biofilm by amphotericin B or tyrosol was found to be concentration dependent, with 50% reduction (P < 0.05) at 4mg/l and 80μM, respectively. Hence, a combination effect of tyrosol and amphotericin B was studied. Interestingly, approximately 90% reduction in biofilm was observed with use of 80μM tyrosol combined with 4mg/l amphotericin B (P < 0.001). This represents a first step in establishing an appropriate antibiofilm therapy when yeasts are present.

Original languageEnglish (US)
Pages (from-to)853-861
Number of pages9
JournalMedical Mycology
Volume52
Issue number8
DOIs
StatePublished - Oct 27 2014

Fingerprint

Candida tropicalis
Intrauterine Devices
Amphotericin B
Biofilms
Candida
Contraceptive Devices
Candidiasis
4-hydroxyphenylethanol
Yeasts
Therapeutics

All Science Journal Classification (ASJC) codes

  • Infectious Diseases

Cite this

Shanmughapriya, Santhanam ; Sornakumari, Haridevvenkatesan ; Lency, Arumugam ; Kavitha, Senthil ; Natarajaseenivasan, Kalimuthusamy. / Synergistic effect of amphotericin B and tyrosol on biofilm formed by Candida krusei and Candida tropicalis from intrauterine device users. In: Medical Mycology. 2014 ; Vol. 52, No. 8. pp. 853-861.
@article{67043417134e481e938a0a4bfea186eb,
title = "Synergistic effect of amphotericin B and tyrosol on biofilm formed by Candida krusei and Candida tropicalis from intrauterine device users",
abstract = "The presence of intrauterine contraceptive devices (IUDs) provides a solid surface for attachment of microorganisms and an ideal niche for the biofilm to form and flourish. Vaginal candidiasis is often associated with the use of IUDs. Treatment of vaginal candidiasis that develops in connection with IUD use requires their immediate removal. Here, we present in vitro evidence to support the use of combination therapy to inhibit Candida biofilm. Twenty-three clinical Candida isolates (10 C. krusei and 13 C. tropicalis) recovered from endocervical swabs obtained from IUD and non-IUD users were assessed for biofilm-formation ability. The rate of isolation of Candida did not differ significantly among IUD and non-IUD users (P = 0.183), but the biofilm-formation ability of isolates differed significantly (P = 0.02). An in vitro biofilm model with the obtained isolates was subjected to treatment with amphotericin B, tyrosol, and a combination of amphotericin B and tyrosol. Inhibition of biofilm by amphotericin B or tyrosol was found to be concentration dependent, with 50{\%} reduction (P < 0.05) at 4mg/l and 80μM, respectively. Hence, a combination effect of tyrosol and amphotericin B was studied. Interestingly, approximately 90{\%} reduction in biofilm was observed with use of 80μM tyrosol combined with 4mg/l amphotericin B (P < 0.001). This represents a first step in establishing an appropriate antibiofilm therapy when yeasts are present.",
author = "Santhanam Shanmughapriya and Haridevvenkatesan Sornakumari and Arumugam Lency and Senthil Kavitha and Kalimuthusamy Natarajaseenivasan",
year = "2014",
month = "10",
day = "27",
doi = "10.1093/mmy/myu046",
language = "English (US)",
volume = "52",
pages = "853--861",
journal = "Medical Mycology",
issn = "1369-3786",
publisher = "Informa Healthcare",
number = "8",

}

Synergistic effect of amphotericin B and tyrosol on biofilm formed by Candida krusei and Candida tropicalis from intrauterine device users. / Shanmughapriya, Santhanam; Sornakumari, Haridevvenkatesan; Lency, Arumugam; Kavitha, Senthil; Natarajaseenivasan, Kalimuthusamy.

In: Medical Mycology, Vol. 52, No. 8, 27.10.2014, p. 853-861.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Synergistic effect of amphotericin B and tyrosol on biofilm formed by Candida krusei and Candida tropicalis from intrauterine device users

AU - Shanmughapriya, Santhanam

AU - Sornakumari, Haridevvenkatesan

AU - Lency, Arumugam

AU - Kavitha, Senthil

AU - Natarajaseenivasan, Kalimuthusamy

PY - 2014/10/27

Y1 - 2014/10/27

N2 - The presence of intrauterine contraceptive devices (IUDs) provides a solid surface for attachment of microorganisms and an ideal niche for the biofilm to form and flourish. Vaginal candidiasis is often associated with the use of IUDs. Treatment of vaginal candidiasis that develops in connection with IUD use requires their immediate removal. Here, we present in vitro evidence to support the use of combination therapy to inhibit Candida biofilm. Twenty-three clinical Candida isolates (10 C. krusei and 13 C. tropicalis) recovered from endocervical swabs obtained from IUD and non-IUD users were assessed for biofilm-formation ability. The rate of isolation of Candida did not differ significantly among IUD and non-IUD users (P = 0.183), but the biofilm-formation ability of isolates differed significantly (P = 0.02). An in vitro biofilm model with the obtained isolates was subjected to treatment with amphotericin B, tyrosol, and a combination of amphotericin B and tyrosol. Inhibition of biofilm by amphotericin B or tyrosol was found to be concentration dependent, with 50% reduction (P < 0.05) at 4mg/l and 80μM, respectively. Hence, a combination effect of tyrosol and amphotericin B was studied. Interestingly, approximately 90% reduction in biofilm was observed with use of 80μM tyrosol combined with 4mg/l amphotericin B (P < 0.001). This represents a first step in establishing an appropriate antibiofilm therapy when yeasts are present.

AB - The presence of intrauterine contraceptive devices (IUDs) provides a solid surface for attachment of microorganisms and an ideal niche for the biofilm to form and flourish. Vaginal candidiasis is often associated with the use of IUDs. Treatment of vaginal candidiasis that develops in connection with IUD use requires their immediate removal. Here, we present in vitro evidence to support the use of combination therapy to inhibit Candida biofilm. Twenty-three clinical Candida isolates (10 C. krusei and 13 C. tropicalis) recovered from endocervical swabs obtained from IUD and non-IUD users were assessed for biofilm-formation ability. The rate of isolation of Candida did not differ significantly among IUD and non-IUD users (P = 0.183), but the biofilm-formation ability of isolates differed significantly (P = 0.02). An in vitro biofilm model with the obtained isolates was subjected to treatment with amphotericin B, tyrosol, and a combination of amphotericin B and tyrosol. Inhibition of biofilm by amphotericin B or tyrosol was found to be concentration dependent, with 50% reduction (P < 0.05) at 4mg/l and 80μM, respectively. Hence, a combination effect of tyrosol and amphotericin B was studied. Interestingly, approximately 90% reduction in biofilm was observed with use of 80μM tyrosol combined with 4mg/l amphotericin B (P < 0.001). This represents a first step in establishing an appropriate antibiofilm therapy when yeasts are present.

UR - http://www.scopus.com/inward/record.url?scp=84914118495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84914118495&partnerID=8YFLogxK

U2 - 10.1093/mmy/myu046

DO - 10.1093/mmy/myu046

M3 - Article

C2 - 25202127

AN - SCOPUS:84914118495

VL - 52

SP - 853

EP - 861

JO - Medical Mycology

JF - Medical Mycology

SN - 1369-3786

IS - 8

ER -